Correlation of serum IL-2, IL-6 and IL-10 levels with international prognostic index in patients with aggressive non-Hodgkin's lymphoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 6, 2002, Pages 570-572

  Aydin, Fazil ^a   Yilmaz, Mustafa ^a   Özdemir, Feyyaz ^a   Kavgaci, Halil ^a   Yavuz, Melek Nur ^a   Yavuz, Ali Aydin ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Aggressive non Hodgkin's lymphoma; Interleukin 10; Interleukin 2; Interleukin 6; International Prognostic Index

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PROGNOSIS; RISK ASSESSMENT; SERUM;

BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKINS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS;

EID: 0036901177     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200212000-00007     Document Type: Article

References (16)

1. Armitage JO. Mauch PM, Harris NL, et al. Non-Hodgkin's lymphomas. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 6th Ed. Philadelphia: Lippincott Williams & Wilkins, 2001:2236-316.
2. Shipp M, Harrington D, Anderson J, et al. A predictive model for aggressive non-Hodgkin's lymphoma: The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987-94.
3. Aydin F, Ulusoy S, Ovali E. Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the international prognostic index. J Chemother 1997;9:446-51.
4. Cortes JE, Talpaz M, Cabanillas F, et al. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: Lack of correlation with prognosis. Blood 1995;85:2516-20.
5. Hsu SM, Waldron JW Jr, Hsu PL, et al. Cytokines in malignant lymphomas: Review and prospective evaluation. Hum Pathol 1993;24:1040-57.
6. Preti HA, Cabanillas F, Talpaz M, et al. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997;127:186-94.
7. Stasi R, Zinzani PL, Galiani P, et al. Clinical implications of cytokines and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 1995;54:9-17.
8. Stasi R, Zinzani PL, Galieni P, et al. Prognostic value of interleukin-10 and soluble interleukin-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994;88:770-7.
9. Blay JY, Burdin N, Prosset F, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor. Blood 1993;82:2169-74.
10. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma 1997;26:251-9.
11. Seymour JF, Talpaz M, Cabanillas F, et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13:373-82.
12. Beaty RM, Rulli K, Bost KL, et al. High levels of IL-4 and IL-10 mRNA and low levels of IL-2, IL-9 and IFN-gamma mRNA in MuLV-induced lymphomas. Virology 1999;261:253-62.
13. Kato H, Kinoshita T, Suzuki S, et al. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1997;29:71-9.
14. Kato H, Kinoshita T, Suzuki S, et al. Elevated serum interleukin-6 is derived from neoplastic lymphoid cells in patients with B cell non-Hodgkin's lymphoma: Correlation with extent of interleukin-6 expression and serum concentration. Br J Haematol 1996;92:1014-21.
15. Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cell and act as cooperative growth factors. Cancer Res 1996;56:5499-505.
16. Emilie D, Coumbaras J, Raphael M, et al. Interleukin-6 production in high grade B lymphomas: Correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood 1992;80:498-504.